Price | 1784€+ Login to see price |
Organism | Human |
Product Type | Organoid |
Tissue | Bile ducts of the liver |
Disease | Cholangiocarcinoma |
Applications
Oncology
Small Molecule
Antibody
Cancer Vaccine
mRNA
Immune Cell
TME-CAF
Immuno Oncology
Macrophage
Regulatory T Cell
Tumor-Infiltrating Lymphocyte
Cytotoxic T Cell
Our hCCA organoids accurately replicate patient tumors by expressing key markers CK7 and CEA underscoring their fidelity for cancer research and personalized treatment development.
This molecular mimicry enables a profound understanding of bile duct cancer pathology and offers a promising avenue for therapeutic innovations.
H&E | CK7 | CEA | CA-19-9 | |
|---|---|---|---|---|
Cancer tissue |  |  |  |  |
Cancer organoid |  |  |  |  |
 |  |  |  |
Unlock the essence of precision in cancer treatment with our CCA organoids, mirroring the genetic markers of Cholangiocarcinoma. Experience the future of testing you drugs, serving as an invaluable tool in capturing the patient-specific characteristics, thereby providing a more accurate platform for studying tumor biology and testing Dive into a new era of oncology, where your individuality guides our innovation.
Our WES analysis of 5 cholangiocarcinoma (hCCA) samples has shown that the top 30 gene mutations are prominently present across all samples, indicating a high level of mutation.
These findings suggest that conducting experiments with our diverse range of gastric cancer samples is likely to produce results closely mirroring those observed in actual human cases.
Using hCCA Organoid, we statistically analyze the correlation between genetic mutations in proteins and protein-to-protein databases to confirm the associative relationships of genes.
Embrace personalized medicine with our cutting-edge platform: Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses.
Transform the standard with us—where your medication’s potential is as unique as you are.
hCCA Gemcitabine
hCCA Cisplatin
hCCA Paclitaxel
hCCA 5-FU
We have confirmed varying efficacy among patients when treating Cholangiocarcinoma organoids derived from patients with representative chemotherapeutic agents such as gemcitabine, Cisplatin, Paclitaxel and 5-FU.
This underscores the potential for selecting personalized drugs tailored to each patient.
Furthermore, matching these treatments with patients genetic profiles could significantly aid in selecting appropriate chemotherapy agents.
We aim to contribute to the advancement of personalized cancer therapy based on these findings.
